ENANTA PHARMACEUTICALS, INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ENANTA PHARMACEUTICALS, INC (ENTA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.58 million shares for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2022-08-08
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-06-30 was 4.58M shares, a 6.02% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-03-31 was 3.70M shares, a 13.33% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-12-31 was 2.84M shares, a 34.55% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-06-30 was 4.32M shares, a 18.74% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 4.30M shares, a 22.70% increase from fiscal 2020.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 3.50M shares, a 315.42% increase from fiscal 2019.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 843.00K shares, a 185.76% increase from fiscal 2018.
- ENANTA PHARMACEUTICALS, INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2018 was 295.00K shares, a 86.35% decline from fiscal 2017.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | 4.58M shares 10-Q · filed 2022-08-08 | 5.56M shares 10-Q · filed 2022-08-08 | ||||||
| 2022-03-31 | 3.70M shares 10-Q · filed 2022-05-09 | 3.27M shares 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | 2.84M shares 10-Q · filed 2022-02-10 | |||||||
| 2021-09-30 | 4.30M shares 10-K · filed 2021-11-24 | |||||||
| 2021-06-30 | 4.32M shares 10-Q · filed 2022-08-08 | 6.47M shares 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | 4.27M shares 10-Q · filed 2022-05-09 | 4.31M shares 10-Q · filed 2022-05-09 | ||||||
| 2020-12-31 | 4.34M shares 10-Q · filed 2022-02-10 | |||||||
| 2020-09-30 | 3.50M shares 10-K · filed 2021-11-24 | |||||||
| 2020-06-30 | 3.64M shares 10-Q · filed 2021-08-09 | 3.42M shares 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | 3.71M shares 10-Q · filed 2021-05-10 | 2.46M shares 10-Q · filed 2021-05-10 | ||||||
| 2019-12-31 | 1.90M shares 10-Q · filed 2021-02-09 | |||||||
| 2019-09-30 | 843.00K shares 10-K · filed 2021-11-24 | |||||||
| 2019-06-30 | 830.00K shares 10-Q · filed 2020-08-10 | 740.00K shares 10-Q · filed 2020-08-10 | ||||||
| 2019-03-31 | 784.00K shares 10-Q · filed 2020-05-11 | 694.00K shares 10-Q · filed 2020-05-11 | ||||||
| 2018-12-31 | 606.00K shares 10-Q · filed 2020-02-10 | |||||||
| 2018-09-30 | 295.00K shares 10-K · filed 2020-11-25 | |||||||
| 2018-06-30 | 117.00K shares 10-Q · filed 2019-08-09 | 338.00K shares 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | 46.00K shares 10-Q · filed 2019-05-10 | 449.00K shares 10-Q · filed 2019-05-10 | ||||||
| 2017-12-31 | 842.00K shares 10-Q · filed 2019-02-08 | |||||||
| 2017-09-30 | 2.16M shares 10-K · filed 2019-11-27 | |||||||
| 2017-06-30 | 2.24M shares 10-Q · filed 2018-08-09 | 1.83M shares 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | 2.53M shares 10-Q · filed 2018-05-10 | 2.55M shares 10-Q · filed 2018-05-10 | ||||||
| 2016-12-31 | 2.58M shares 10-Q · filed 2018-02-09 | |||||||
| 2016-09-30 | 1.48M shares 10-K · filed 2018-11-29 | 1.48K shares 10-K · filed 2016-12-09 | ||||||
| 2016-06-30 | 1.62M shares 10-Q · filed 2017-08-09 | 1.62M shares 10-Q · filed 2016-08-09 | 1.25M shares 10-Q · filed 2017-08-09 | 1.25M shares 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | 1.66M shares 10-Q · filed 2017-05-10 | 1.66M shares 10-Q · filed 2016-05-10 | 1.19M shares 10-Q · filed 2017-05-10 | 1.18M shares 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | 1.12M shares 10-Q · filed 2017-02-09 | |||||||
| 2015-09-30 | 605.00K shares 10-K · filed 2017-12-11 | 605.00 shares 10-K · filed 2016-12-09 | ||||||
| 2015-06-30 | 700.68K shares 10-Q · filed 2016-08-09 | 599.38K shares 10-Q · filed 2016-08-09 | ||||||
| 2015-03-31 | 696.45K shares 10-Q · filed 2016-05-10 | 489.12K shares 10-Q · filed 2016-05-10 | ||||||
| 2014-09-30 | 330.00 shares 10-K · filed 2016-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |